MarketPulse

EGFR

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Alx Oncology Holdings Inc.

ALX Oncology Narrows Losses, Secures Funding as Clinical Pipeline Advances

ALX Oncology reduced losses and secured $150M in funding, extending cash runway to mid-2028. The company advances its clinical pipeline with CD47 biomarker validation for its cancer therapies.
ALXOclinical trialsevorpacept
BenzingaBenzinga··Globe Newswire

Bicara Therapeutics Raises $172.5M in Oversubscribed Offering

Bicara Therapeutics raises $172.5M in oversubscribed offering, with proceeds funding development of lead immunotherapy candidate ficerafusp alfa for solid tumors.
BCAXclinical-stageEGFR
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Bicara Therapeutics Raises $150M Through Stock and Warrant Offering

Bicara Therapeutics raises $150M through stock and warrant offering to fund lead drug candidate development, expand manufacturing, and build commercial infrastructure.
BCAXEGFRpublic offering
BenzingaBenzinga··Globe Newswire

Bicara Therapeutics Plans $150M Stock Offering to Fund Pipeline Advancement

Bicara Therapeutics plans $150M stock offering to advance its lead drug candidate ficerafusp alfa through clinical development and build commercial infrastructure for potential market launch.
BCAXclinical-stageEGFR
BenzingaBenzinga··Vandana Singh

Novartis Kidney Drug Demonstrates Sustained Efficacy in Long-Term Study Data

Novartis's kidney drug Vanrafia shows sustained efficacy in slowing kidney function decline, supporting its path to full regulatory approval in 2026 for IgA nephropathy treatment.
NVSkidney diseaseEGFR